An Update on Pharmacogenomic and Pharmacogenetic Challenges in Cardiovascular Diseases and Psychiatric Disorders

A special issue of Pharmaceutics (ISSN 1999-4923).

Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 1675

Special Issue Editor

Ribeirao Preto College of Nursing – University of Sao Paulo, São Paulo 14040-902, Brazil
Interests: pharmacogenetics; pharmacogenomics; genetics of complex traits; epigenetics

Special Issue Information

Dear Colleagues,

The first draft of the human genome was published a little more than 20 years ago. One of the main promises was to make it possible to personalize drug therapy, increasing safety and clinical efficacy in many different clinical settings. After 20 years, the costs have lowered substantially, and there are several examples of the use of pharmacogenetics in clinics, but some areas show more advances than others. While cancer therapy is very advanced, showing even new treatments developed for specific mutations in tumoral tissue, there are few examples in cardiovascular and psychiatric areas that are of clinical importance today. However, there is huge potential to uncover new pharmacogenetic targets and, in doing so, help to shed light on new drug targets and pathogenesis mechanisms that are still poorly understood. It is very interesting that cardiovascular morbidity increases the risk of psychiatric disorders and the reverse is also true. So, it is possible that common mechanisms may be involved in both diseases.

We are pleased to invite you to contribute with manuscripts in cardiovascular or psychiatric pharmacogenetics and pharmacogenomics research. This special Issue aims to publish a collection of articles regarding new candidate genes, genome-wide analysis and pharmacogenetic and genomic data that may help to better understand the dynamics between altered pathways and predisposition to disease and the clinical failure of drug therapies in cardiovascular and psychiatric diseases.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following: genomic-wide data, candidate genes as vascular endothelial growth factor, matrix metalloproteinases, adipokines, brain derived neurotrophic factor, or pathways involved in oxidative stress, blood–brain barrier dynamics (or other membrane barriers), neuroinflammation, corticoid signaling affecting cardiovascular disease or psychiatric disorders and drug therapy.

I look forward to receiving your contributions.

Dr. Riccardo Lacchini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular disease
  • psychiatric disorders
  • pharmacogenetics
  • gene polymorphisms
  • inflammation
  • oxidative stress
  • endocrine factors

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 608 KiB  
Review
Pharmacogenetic Guidelines for Psychotropic Drugs: Optimizing Prescriptions in Clinical Practice
by Antoine Baldacci, Emeric Saguin, Alexander Balcerac, Stéphane Mouchabac, Florian Ferreri, Raphael Gaillard, Marie-Dominique Colas, Hervé Delacour and Alexis Bourla
Pharmaceutics 2023, 15(11), 2540; https://doi.org/10.3390/pharmaceutics15112540 - 27 Oct 2023
Viewed by 1296
Abstract
The modalities for prescribing a psychotropic (dose and choice of molecule) are currently unsatisfactory, which can lead to a lack of efficacy of the treatment associated with prolonged exposure of the patient to the symptoms of his or her illness and the side [...] Read more.
The modalities for prescribing a psychotropic (dose and choice of molecule) are currently unsatisfactory, which can lead to a lack of efficacy of the treatment associated with prolonged exposure of the patient to the symptoms of his or her illness and the side effects of the molecule. In order to improve the quality of treatment prescription, a part of the current biomedical research is dedicated to the development of pharmacogenetic tools for individualized prescription. In this guideline, we will present the genes of interest with level 1 clinical recommendations according to PharmGKB for the two major families of psychotropics: antipsychotics and antidepressants. For antipsychotics, there are CYP2D6 and CYP3A4, and for antidepressants, CYP2B6, CYP2D6, and CYP2C19. The study will focus on describing the role of each gene, presenting the variants that cause functional changes, and discussing the implications for prescriptions in clinical practice. Full article
Show Figures

Figure 1

Back to TopTop